Flu Vaccine for Adults
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or long-term systemic corticosteroids, you may not be eligible to participate.
What data supports the effectiveness of the treatment Quadrivalent Influenza mRNA Vaccine MRT5421, MRT5424, and MRT5429?
Research on similar mRNA-based influenza vaccines shows promising results. A quadrivalent mRNA vaccine was found to induce strong immune responses and protect against influenza in animal studies, and another mRNA vaccine (mRNA-1010) showed higher immune responses compared to standard vaccines in human trials.12345
Is the quadrivalent mRNA flu vaccine safe for adults?
How is the Quadrivalent Influenza mRNA Vaccine different from other flu vaccines?
The Quadrivalent Influenza mRNA Vaccine is unique because it uses mRNA technology, which instructs cells to produce a protein that triggers an immune response, unlike traditional vaccines that use inactivated or recombinant virus components. This approach can potentially offer a more robust immune response and faster production times compared to conventional flu vaccines.358910
What is the purpose of this trial?
This trial is testing new mRNA flu vaccines in adults aged 18 and older. The vaccines work by using genetic instructions to help the body recognize and fight the flu virus. The study aims to see if these new vaccines are safe and effective. The first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses were evaluated for safety and effectiveness over a period of several years.
Eligibility Criteria
Adults aged 18 and older can join this study to test new flu vaccines. People with a history of severe allergic reactions to any vaccine ingredients or who are immunocompromised may not be eligible.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular injection of one of the Quadrivalent Influenza mRNA Vaccines or a control
Follow-up
Participants are monitored for safety and immunogenicity, including adverse events and antibody titers
Treatment Details
Interventions
- Quadrivalent Influenza mRNA Vaccine MRT5421
- Quadrivalent Influenza mRNA Vaccine MRT5424
- Quadrivalent Influenza mRNA Vaccine MRT5429
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi Pasteur, a Sanofi Company
Lead Sponsor
Paul Hudson
Sanofi Pasteur, a Sanofi Company
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Dr. Thomas Triomphe
Sanofi Pasteur, a Sanofi Company
Chief Medical Officer since 2020
MD from Tehran University of Medical Sciences